A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders

BioFactors

Volumn 42, Issue 1, 2016, Pages 93-105

  Papa Gobbi, Rodrigo ^a   De Francesco, Nicolás ^a   Bondar, Constanza ^a   Muglia, Cecilia ^a   Chirdo, Fernando ^a   Rumbo, Martín ^a   Rocca, Andrés ^c   Toscano, Marta A ^b   Sambuelli, Alicia ^c   Rabinovich, Gabriel A ^b,d   Docena, Guillermo H ^a  

^a Universidad Nacional de La Plata   (Argentina)

^b Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

^c HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Biomarkers; Crohn disease; Galectins; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 3; GALECTIN 4; MESSENGER RNA; 1-NITROHYDROXYPHENYL-N-BENZOYLALANINE; BENZAMIDE DERIVATIVE; LGALS9 PROTEIN, HUMAN; TYROSINE;

ADULT; AGED; ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DISCRIMINANT ANALYSIS; ENTEROPATHY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; ANALOGS AND DERIVATIVES; BIOPSY; BIOSYNTHESIS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

ADULT; BENZAMIDES; BIOPSY; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GALECTIN 3; GALECTIN 4; GALECTINS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES; MALE; RNA, MESSENGER; TYROSINE;

EID: 84959363220     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1252     Document Type: Article

References (45)

1. Cooper, D. N. W. (2002) Galectinomics: finding themes in complexity. Biochim. Biophys. Acta 1572, 209-231. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12223271 [Accessed July 7, 2015].
2. Liu, F. -T. and Rabinovich, G. (2005) Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15630413 [Accessed June 16, 2014].
3. Ilarregui, J. M., Croci, D. O., Bianco, G. A., Toscano, M. A., Salatino, M., et al. (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10, 981-991. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19668220 [Accessed June 10, 2014].
4. Toscano, M. A., Ilarregui, J. M., Bianco, G. A., Campagna, L., Croci, D. O., et al. (2014) Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity? Cytokine Growth Factor Rev. 18, 57-71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17321195 [Accessed June 23
5. Toscano, M. A., Bianco, G. A., Ilarregui, J. M., Croci, D. O., Correale, J., et al. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8, 825-834. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17589510 [Accessed June 10, 2014].
6. Rubinstein, N., Ilarregui, J. M., Toscano, M. A., Rabinovich, G. A. (2004) The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 64, 1-12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15191517 [Accessed June 27, 2014].
7. Müller, S., Schaffer, T., Flogerzi, B., Fleetwood, A., Weimann, R., et al. (2006) Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm. Bowel Dis. 12, 588-597. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16804396 [Accessed June 23, 2014].
8. Paclik, D., Danese, S., Berndt, U., Wiedenmann, B., Dignass, A., et al. (2008) Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One 3, e2629 Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2440804&tool=pmcentrez&rendertype=abstract [Accessed June 16, 2014].
9. Paclik, D., Berndt, U., Guzy, C., Dankof, A., Danese, S., et al. (2008) Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J. Mol. Med. (Berl). 86, 1395-1406. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18064431 [Accessed June 16, 2014].
10. Nio-Kobayashi, J., Takahashi-Iwanaga, H., and Iwanaga, T. (2009) Immunohistochemical localization of six galectin subtypes in the mouse digestive tract. J. Histochem. Cytochem. 57, 41-50. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2605710&tool=pmcentrez&rendertype= abstract [Accessed December 12, 2014].
11. Kaltner, H., Seyrek, K., Heck, A., Sinowatz, F., Gabius, H. J. (2002) Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res. 307, 35-46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11810312 [Accessed December 12, 2014].
12. Xavier, R. J. and Podolsky, D. K. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17653185 [Accessed May 24, 2014].
13. Baumgart, D. C. and Sandborn, W. J. (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369, 1641-1657. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17499606 [Accessed January 18, 2015].
14. Baumgart, D. C. and Carding, S. R. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627-1640.
15. Lippert, E., Falk, W., Bataille, F., Kaehne, T., Naumann, M., et al. (2007) Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut 56, 43-51. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1856646&tool=pmcentrez&rendertype=abstract [Accessed June 16, 2014].
16. Gitt, M. A., Colnot, C., Poirier, F., Nani, K. J., Barondes, S. H., et al. (1998) Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract. J. Biol. Chem. 273, 2954-2960. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9446608 [Accessed June 23, 2014].
17. Srikrishna, G., Turovskaya, O., Shaikh, R., Newlin, R., Foell, D., et al. (2005) Carboxylated glycans mediate colitis through activation of NF-kappa B. J. Immunol. 175, 5412-5422. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16210648 [Accessed June 23, 2014].
18. Lippert, E., Gunckel, M., Brenmoehl, J., Bataille, F., Falk, W., et al. (2008) Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clin. Exp. Immunol. 152, 285-297. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2384104&tool=pmcentrez&rendertype=abstract [Accessed June 16, 2014].
19. Morimoto, K., Hosomi, S., Yamagami, H., Watanabe, K., Kamata, N., et al. (2011) Dysregulated upregulation of T-cell immunoglobulin and mucin domain-3 on mucosal T helper 1 cells in patients with Crohn's disease. Scand. J. Gastroenterol. 46, 701-709. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21463244 [Accessed June 23, 2014].
20. Lennard-Jones, J. E. (1989) Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 170, 2-6. discussion 16-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2617184 [Accessed January 26, 2015].
21. Lewis, J. D., Chuai, S., Nessel, L., Lichtenstein, G. R., Aberra, F. N., et al. (2008) Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm. Bowel Dis. 14, 1660-1666. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2597552&tool=pmcentrez&rendertype=abstract [Accessed September 9, 2015].
22. Harvey, R. F. and Bradshaw, J. M. (1980) A simple index of Crohn's-disease activity. Lancet (London, England) 1, 514 Available at: http://www.ncbi.nlm.nih.gov/pubmed/6102236 [Accessed October 7, 2015].
23. Panaccione, R., Loftus, E. V., Jr., Binion, D., McHugh, K., Alam, S., et al. (2011) Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can. J. Gastroenterol. 25, 419-425. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3186726&tool=pmcentrez&rendertype=abstract [Accessed October 7, 2015].
24. Frøslie, K. F., Jahnsen, J., Moum, B., Vatn, M. H. (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412-422. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17681162 [Accessed November 14, 2014].
25. Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., et al. (2013) European evidence based consensus for endoscopy in inflammatory bowel disease. J. Crohns Colitis. 7, 982-1018. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24184171 [Accessed November 6, 2014].
26. Saverymuttu, S. H., Camilleri, M., Rees, H., Lavender, J. P., Hodgson, H. J., et al. (1986) Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 90, 1121-1128. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3956932.
27. Villanacci, V., Antonelli, E., Geboes, K., Casella, G., Bassotti, G. (2013) Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J. Gastroenterol. 19, 968-978. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3582008&tool=pmcentrez&rendertype=abstract [Accessed November 14, 2014].
28. Nishida, S., Hadjis, N. S., Levi, D. M., Kato, T., Vaidya, A., Nery, J. R. (2004) Intestinal and multivisceral transplantation after abdominal trauma. J. Trauma 56, 323-327. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14960974 [Accessed February 3, 2015].
29. Sylvester, K. G., Ling, X. B., Liu, G. Y., Kastenberg, Z. J., Ji, J., et al. (2013) A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants. Gut 1-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24048736 [Accessed June 23, 2014].
30. Santucci, L., Fiorucci, S., Rubinstein, N., Mencarelli, A., Palazzetti, B., et al. (2003) Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124, 1381-1394. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0016508503002671 [Accessed June 16, 2014].
31. Shan, M., Gentile, M., Yeiser, J. R., Walland, A. C., Bornstein, V. U., et al. (2013) Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 342, 447-453. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4005805&tool=pmcentrez&rendertype=abstract [Accessed June 22, 2015].
32. Nishida, A., Lau, C. W., and Mizoguchi, A. (2015) Examination of the role of galectins in intestinal inflammation. Methods Mol. Biol. 1207, 231-248. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25253144 [Accessed July 7, 2015].
33. Leij, J., van der Berg, A., van den Harms, G., Eschbach, H., Vos, H., et al. (2007) Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol. Immunol. 44, 506-513. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16581128 [Accessed June 23, 2014].
34. Nishida, A., Nagahama, K., Imaeda, H., Ogawa, A., Lau, C. W., et al. (2012) Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells. J. Exp. Med. 209, 2383-2394. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3526363&tool=pmcentrez&rendertype=abstract [Accessed June 22, 2014].
35. Hokama, A., Mizoguchi, E., Sugimoto, K., Shimomura, Y., Tanaka, Y., et al. (2004) Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20, 681-693. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15189734 [Accessed June 23, 2014].
36. Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16286920 [Accessed June 4, 2014].
37. Shi, F., Guo, X., Jiang, X., Zhou, P., Xiao, Y., et al. (2012) Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis. Clin. Immunol. 145, 230-240. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23117395 [Accessed November 14, 2014].
38. Christophi, G. P., Rong, R., Holtzapple, P. G., Massa, P. T., Landas, S. K. (2012) Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 18, 2342-2356. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3407828&tool=pmcentrez&rendertype=abstract [Accessed June 16, 2014].
39. Neurath, M. F. (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129-1143. Available at: http://www.jem.org/cgi/doi/10.1084/jem.20011956 [Accessed June 16, 2014].
40. Starossom, S. C., Mascanfroni, I. D., Imitola, J., Cao, L., Raddassi, K., et al. (2012) Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37, 249-263.
41. Molander, P., Färkkilä, M., Ristimäki, A., Salminen, K., Kemppainen, H., et al. (2015) Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J. Crohns Colitis. 9, 33-40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25052347 [Accessed September 2, 2015].
42. García-Sánchez, V., Iglesias-Flores, E., González, R., Gisbert, J. P., Gallardo-Valverde, J. M., González-Galilea, A., Naranjo-Rodríguez, A., de Dios-Vega, J. F., MuntanÕ, J., Gómez-Camacho, F. (2010) Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J. Crohns Colitis. 4, 144-152. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21122498 [Accessed September 14, 2015].
43. Høie, O., Aamodt, G., Vermeire, S., Bernklev, T., Odes, S., et al. (2008) Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J. Crohns Colitis. 2, 114-122. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21172201 [Accessed September 16, 2015].
44. Bouguen, G., Levesque, B. G., Feagan, B. G., Kavanaugh, A., Peyrin-Biroulet, L., et al. (2015) Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin. Gastroenterol. Hepatol. 13, 1042-1050.e2. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1542356513013013.
45. Travis, S. P., Higgins, P. D., Orchard, T., Van Der Woude, C. J., Panaccione, R., et al. (2011) Review article: defining remission in ulcerative colitis. Aliment. Pharmacol. Ther. 34, 113-124. Available at: http://doi.wiley.com/10.1111/j.1365-2036.2011.04701.x.